What is Ionpath?
Ionpath, Inc. is a trailblazer in high-definition spatial proteomics, fundamentally transforming tissue imaging and analysis to accelerate medical breakthroughs and enhance human health. The company's proprietary MIBI (multiplexed ion beam imaging) platform surpasses the limitations of conventional immunohistochemistry (IHC), offering unprecedented depth in understanding the tissue microenvironment. This is achieved through highly multiplexed, quantitative single-cell analysis, providing critical insights for researchers in immuno-oncology, immunology, neuroscience, and infectious disease research across leading pharmaceutical, biotechnology, and academic organizations.
How much funding has Ionpath raised?
Ionpath has raised a total of $20M across 3 funding rounds:
Debt
$1M
Series B
$18M
Debt
$1M
Debt (2020): $1M with participation from PPP
Series B (2020): $18M led by Genoa Ventures, Norwich Ventures, Paladin Partners Investments, Trancos IONpath Investors, ND Capital, Samsara BioCapital, Vertical Venture Partners Growth Fund, and Bruker Corporation
Debt (2021): $1M supported by PPP
Key Investors in Ionpath
Genoa Ventures
Genoa Ventures is an investment firm that likely focuses on early-stage technology companies, potentially within the life sciences or deep tech sectors, given its name and typical VC investment patterns.
Norwich Ventures
Norwich Ventures is a specialized venture capital firm established in 2004, focusing on early-stage medtech investments. The firm seeks to support entrepreneurs developing innovative technologies that address significant unmet medical needs.
Samsara BioCapital
Samsara BioCapital is a venture capital firm that invests in biotechnology and life sciences companies, likely focusing on innovative therapeutics and platforms that address significant unmet medical needs.
What's next for Ionpath?
The substantial enterprise-level funding positions Ionpath for significant scaling and further development of its MIBI technology. This strategic investment is expected to fuel expansion into new research areas and clinical applications, reinforcing its market leadership in spatial proteomics. The company is poised to deepen its impact on translational and clinical research, driving innovation in disease understanding and therapeutic development.
See full Ionpath company page
